TABLE 2

Evaluation of susceptibilities to azole drugs conferred by expression of native and recombinant LDMs and a cognate Ncp1pa

StrainStrain descriptionRatio of MIC80 values
AMBFLCVCZVT-1161ITCPCZ
Y2300/Y2411Host 2 PDR5::ScERG11 ΔScERG11/Host 21.1 ± 0.33.3 ± 1.23.4 ± 0.93.4 ± 0.71.6 ± 0.31.9 ± 0.6
Y2461/Y2411Host 2 PDR15::ScERG11/Host 21.4 ± 0.23.6 ± 0.73.9 ± 0.83.3 ± 0.71.8 ± 0.32.0 ± 0.4
Y2460/Y2411Host 2 PDR5::ScNCP1/Host 20.7 ± 0.21.5 ± 0.41.9 ± 0.51.6 ± 0.20.9 ± 0.20.8 ± 0.3
Y2462/Y2411Host 2 PDR5::ScNCP1 PDR15::ScERG11/Host 22.1 ± 0.23.7 ± 0.95.1 ± 0.83.1 ± 0.61.4 ± 0.31.7 ± 0.4
Y2462/Y2460Host 2 PDR5::ScNCP1 PDR15::ScERG11/Host 2 PDR5::ScNCP11.0 ± 0.32.5 ± 0.62.7 ± 0.52.0 ± 0.61.6 ± 0.32.0 ± 0.3
Y2374/Y785Host 1 PDR5::CgERG11 ΔScERG11/Host 11.3 ± 0.42.8 ± 0.53.0 ± 1.02.0 ± 0.61.9 ± 0.42.1 ± 0.7
Y2376/Y2411Host 2 PDR15::CaNCP1A/Host 20.7 ± 0.10.9 ± 0.31.1 ± 0.30.8 ± 0.20.8 ± 0.20.7 ± 0.3
Y2458/Y2411Host 2 PDR5::CaErg11 ΔScERG11/Host 20.8 ± 0.21.9 ± 0.41.1 ± 0.21.9 ± 0.31.5 ± 0.41.9 ± 0.7
Y2378/Y2411Host 2 PDR5::CaERG11 PDR15::CaNCP1A/Host 20.7 ± 0.13.1 ± 0.52.7 ± 0.32.4 ± 0.31.5 ± 0.42.0 ± 0.3
Y2459/Y2411Host 2 PDR5::CaERG11 PDR15::CaNCP1A ΔScERG11/Host 20.8 ± 0.12.5 ± 0.51.8 ± 0.22.0 ± 0.41.5 ± 0.41.6 ± 0.6
Y2459/Y2376Host 2 PDR5::CaERG11 PDR15::CaNCP1A ΔScERG11/ Host 2 PDR15::CaNCP1A1.1 ± 0.22.7 ± 0.61.6 ± 0.22.6 ± 0.71.7 ± 0.32.6 ± 0.8
Y2378/Y2459Host 2 PDR5::CaERG11 PDR15::CaNCP1A/ Host 2 PDR5::CaERG11 PDR15::CaNCP1A ΔScERG110.9 ± 0.11.2 ± 0.11.5 ± 0.11.2 ± 0.21.0 ± 0.21.1 ± 0.3
Y2459/Y2458Host 2 PDR5::CaERG11 PDR15::CaNCP1A ΔScERG11/ Host 2 PDR5::CaERG11 ΔScERG111.0 ± 0.21.4 ± 0.11.6 ± 0.11.1 ± 0.21.0 ± 0.20.9 ± 0.2
  • a Host 1 is Y785. Host 2 is Y2411. Results are derived from the data shown in Table 1.